Darragh Duffy, Anna Zychlinsky Scharff, Matthew L. Albert, Livia Lacerda Mariano, Matthieu Rousseau, Tracy Canton, Magnus Fontes, Molly A. Ingersoll, Camila Rosat Consiglio, Immunobiologie des Cellules dendritiques, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), International Group for Data Analysis (IGDA), Institut Pasteur [Paris] (IP), Lund University [Lund], Rigshospitalet [Copenhagen], Copenhagen University Hospital, MAI was supported by funding from the European Union Seventh Framework Programme Marie Curie Action (PCIG11-GA- 2012-3221170) and the Agence Nationale de la Recherché (French National Research Agency) ANR-17-CE17-0014. LLM is part of the Pasteur-Paris University (PPU) International PhD Program, which received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 665807 and from the Labex Milieu Intérieur (ANR-10-LABX-69-01)., We gratefully acknowledge insightful discussions, technical support, and/or critical reading of the manuscript by Drs. Melanie Hamon, Lucy Glover, Jessica Quintin, Vincent Rouilly, Kimberly Kline, Nicolas Serafini, Clémence Hollande, and Björn Albrecht. We acknowledge the Labex Milieu Intérieur and the Technology Core of the Center for Translational Science at the Institut Pasteur for supporting aspects of this study. We thank Dr. Tim Sparwasser for sponsoring the research stay of AZS., ANR-17-CE17-0014,PredictUTI,Identification de biomarqueurs sanguins prédictifs des infections uriniaires récidivantes et développement d'immunothérapies préventives personnalisées(2017), ANR-10-LABX-0069,MILIEU INTERIEUR,GENETIC & ENVIRONMENTAL CONTROL OF IMMUNE PHENOTYPE VARIANCE: ESTABLISHING A PATH TOWARDS PERSONALIZED MEDICINE(2010), European Project: 3221170,European Union Seventh Framework Programme Marie Curie Action, European Project: 665807,H2020,H2020-MSCA-COFUND-2014,PASTEURDOC(2015), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris], Vougny, Marie-Christine, Identification de biomarqueurs sanguins prédictifs des infections uriniaires récidivantes et développement d'immunothérapies préventives personnalisées - - PredictUTI2017 - ANR-17-CE17-0014 - AAPG2017 - VALID, Laboratoires d'excellence - GENETIC & ENVIRONMENTAL CONTROL OF IMMUNE PHENOTYPE VARIANCE: ESTABLISHING A PATH TOWARDS PERSONALIZED MEDICINE - - MILIEU INTERIEUR2010 - ANR-10-LABX-0069 - LABX - VALID, 3221170 - European Union Seventh Framework Programme Marie Curie Action - 3221170 - INCOMING, and Institut Pasteur International Docotal Program - PASTEURDOC - - H20202015-10-01 - 2020-10-01 - 665807 - VALID
International audience; Sex-based differences influence incidence and outcome of infectious disease. Women have a significantly greater incidence of urinary tract infection (UTI) than men, yet, conversely, male UTI is more persistent with greater associated morbidity. Mechanisms underlying these sex-based differences are unknown, in part due to a lack of experimental models. We optimized a model to transurethrally infect male mice and directly compared UTI in both sexes. Although both sexes were initially equally colonized by uropathogenic E. coli, only male and testosterone-treated female mice remained chronically infected for up to 4 weeks. Female mice had more robust innate responses, including higher IL-17 expression, and increased γδ T cells and group 3 innate lymphoid cells in the bladder following infection. Accordingly, neutralizing IL-17 abolished resolution in female mice, identifying a cytokine pathway necessary for bacterial clearance. Our findings support the concept that sex-based responses to UTI contribute to impaired innate immunity in males and provide a rationale for non-antibiotic-based immune targeting to improve the response to UTI.